Posted by Chicago Tribune
CVS-Aetna deal may hinge on antitrust approach under Trump
By Robert Langreth, David Mclaughlin & Zachary Tracer
CVS’ $67.5 billion takeover of Aetna will test the Trump administration’s approach to far-reaching corporate takeovers, just weeks after the US government sued to block a major telecommunications merger.
The health-care deal unveiled Sunday would create an industry giant with over $240 billion in annual sales with a hand in insurance, prescription drug plan administration, retail pharmacies and corner clinics. The companies said the combination will save $750 million in costs and bring consumers better, more efficient health care.
In the past, deals combining companies up and down a chain of business — such as a supplier and a distributor — have been viewed as posing less anticompetitive risk than combinations of direct rivals. Last month, however, the Justice Department sued to block just such a “vertical” merger between AT&T and Time Warner, saying it would harm consumers and limit their media content options.
“We are obviously going to get some scrutiny,” said Aetna Chief Executive Officer Mark Bertolini. “We are prepared to deal with whatever comes along to make this work.”
Aetna shares were trading at $184.84 at 6:33 a.m. in New York, well below CVS’ $207-a-share offer for the company — a sign investors are skeptical the deal will close at the current price.
How much scrutiny the deal gets from the government may depend on which federal agency reviews the takeover — the Justice Department, or the Federal Trade Commission.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI